hepatocellular carcinoma
Conditions
Interventions
Group TILA-TACE:TILA-TACE Therapy
Sponsors
The Second affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Hepatocellular carcinoma is confirmed by tissue pathology or in accordance with clinical diagnosis standard; 2. ECOG score 0-1; 3. HCC BCLC grading 0, A, B, C; 4. Child-Pugh score prior to therapyA and B; 5. As judged by investigators, the patient can comply with the study protocol; 6. Patient voluntarily participates in this study, understands the process of the study, and is willing to sign the written consent form.;Inclusion criteria: 1. Hepatocellular carcinoma is confirmed by tissue pathology or in accordance with clinical diagnosis standard; 2. ECOG score 0-1; 3. HCC BCLC grading 0, A, B, C; 4. Child-Pugh score prior to therapyA and B; 5. As judged by investigators, the patient can comply with the study protocol; 6. Patient voluntarily participates in this study, understands the process of the study, and is willing to sign the written consent form.
Exclusion criteria
Exclusion criteria: 1. HCC BCLC grading D; 2. Child-Pugh score prior to therapyC.;Exclusion criteria: 1. HCC BCLC grading D; 2. Child-Pugh score prior to therapyC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Viable Tumor Residues(%);lifetime;;Viable Tumor Residues(%);lifetime; | — |
Countries
China
Contacts
Public ContactXun Hu;Xun Hu ;
The Second affiliated Hospital, Zhejiang University School of Medicine;The Second affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed